Results 1 to 10 of about 32,246 (220)

Givinostat enhances antisense oligonucleotide efficacy in the <i>mdx52</i> model of Duchenne muscular dystrophy. [PDF]

open access: yesMol Ther Nucleic Acids
Phongsavanh X   +8 more
europepmc   +1 more source

Phenotype rescue through the restoration of full-length dystrophin using CRISPR/Cas9 genome editing in Duchenne muscular dystrophy patient-derived iPSCs carrying the deletion of two exons. [PDF]

open access: yesGenome Med
Rovina D   +14 more
europepmc   +1 more source

Antisense oligonucleotide selection scheme for rare Duchenne muscular dystrophy mutations: Application to <i>DMD</i> exon 16 skipping. [PDF]

open access: yesMol Ther Nucleic Acids
Geoffroy-Guiraud M   +8 more
europepmc   +1 more source

Timing matters: Exon skipping therapy is most effective when initiated early in a mouse model of Duchenne muscular dystrophy. [PDF]

open access: yesMol Ther Nucleic Acids
Stenler S   +8 more
europepmc   +1 more source

Clinical, pathological, and genetic characteristics of 23 DMD patients in northern China. [PDF]

open access: yesOrphanet J Rare Dis
Bu Y   +7 more
europepmc   +1 more source

Exploring Dystrophin Expression and Mutations in the <i>DMD</i> and Dystrophin-Glycoprotein Complex Genes as Prognostic Factors in Leiomyosarcomas. [PDF]

open access: yesInt J Mol Sci
Salazar J   +15 more
europepmc   +1 more source

Microdystrophins partially rescue deficits of Duchenne muscular dystrophy iPSC-cardiomyocytes. [PDF]

open access: yesMol Ther Adv
Keegan AR   +14 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy